Rezūm Water Vapor Therapy is a minimally invasive procedure that uses the natural energy stored in a few drops of water to treat the excess prostate tissue causing BPH symptoms. So you can get back in the game quickly. No need to be in the hospital. And no need to continue taking costly BPH medications.
Powered by convective water vapor energy, the Rezūm System delivers targeted, controlled doses of the stored thermal energy in water vapor directly to the region of the prostate gland with the obstructive tissue causing the lower urinary tract symptoms secondary (LUTS) to benign prostatic hyperplasia (BPH).
First-line therapy option2, 10-point IPSS symptom improvement maintained through 4 years.
In-office treatment removes the complexities of a hospital setting;
Doesn’t require a permanent implant
Able to treat prostates with hyperplasia of the lateral lobes, central zone and/or median lobe
Durable – Low 4.4% procedural retreatment rate through 4 years1
Preserves Sexual Function
Clinical studies show significant improvement in symptoms and quality of life maintained through 4 years.1
Each 9-second treatment uses 0.42ml of heated sterile water vapor which rapidly and uniformly disperses through the tissue interstices. The condensation of water vapor releases stored thermal energy. Cell membranes are denatured, thereby causing immediate cell death, the vasculature is closed, and there is denervation of the alpha-adrenergic nerves within the treatment zone providing you with an efficient, uniform, predictable treatment.
Over time, this ablated tissue is reabsorbed by the body’s natural healing response, reducing the volume of tissue allowing the urethra to open relieving LUTS.
The Rezūm procedure provides the following benefits to men suffering from BPH:
Alternative to BPH medications
Studies support Rezūm relieves symptoms safely and effectively
Noticeable symptom improvement within two weeks
Simple in-office/out-patient therapy
Does not require general anesthesia
Preserves erectile and urinary functions
Faster recovery time
Combining the Efficiency of Convective Thermal Energy and Anatomy
A hand-held delivery device, similar in shape and size to a cystoscope, is connected to a generator. A few drops of sterile water are heated to approximately 103ºC and as the sterile water is transformed from liquid into steam, or vapor, the volume expands by almost 1,700 times and stores 540 calories of thermal energy for every milliliter (mL).
A precise dose of water vapor thermal energy is delivered into the targeted tissue using a small needle with multiple emitter holes to enable controlled and uniform vapor dispersion. The vapor is delivered into the targeted tissue at slightly above interstitial pressure, convectively driving the water vapor through tissue interstices, where it condenses and transfers the stored thermal energy directly to the targeted tissue. This convective heat transfer is what differentiates Rezūm from other ablative thermal therapies that rely on the slower, less precise and less efficient process of conduction to heat tissue.
Convective transfer of water vapor thermal energy to tissue is fast but also self-limiting. Water vapor condenses back into its liquid state as it is dispersed through tissue, so the energy travels no further than its intended area of treatment. The prostate is comprised of three separate zones or regions and the enlarged tissue that causes BPH is located in two of them – the transition zone and the central zone. The tissue separating these zones provides a natural anatomical barrier that contains the vapor within the intended treatment areas.
1. McVary K T, Roehrborn CG, Rogers T. Rezūm water vapor thermal therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia: 4-year results from randomized controlled study. Urology Gold Journal. 2019 Jan 23. [Epub ahead of print]
2. Roehrborn CG, Gange SN, Gittelman MC, et al. Convective water vapor energy (WAVE) ablation therapy: durable two-year results and prospective blinded crossover study for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. J Urol. 2017 Jun;197(6):1507-1516